25B-NB

25B-NBOMe (also known as 2C-B-NBOMe, BOM 2-CB, NBOMe-2C-B, and Cimbi-36) is a psychedelic hallucinogen that is used in biochemistry research for mapping the distribution of serotonin receptors in the brain. It is part of the NBOMe series of N-benzylphenethylamine derivatives.

History

25B-NBOMe was first synthesized in 2004 by Ralf Heim at the Free University of Berlin. It was later investigated by a team at Purdue University led by David Nichols.

Pharmacology

25B-NBOMe acts as a highly potent full agonist for the human 5-HT2A receptor, making it a powerful psychedelic drug. It has been studied in its 18F radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).

Effects

The effects of 25B-NBOMe can vary greatly depending on the dose taken. At lower doses, effects can include feelings of euphoria, visual hallucinations, and increased sensory awareness. At higher doses, effects can include intense hallucinations, severe nausea, panic attacks, and psychosis.

Legal Status

The legal status of 25B-NBOMe varies by country. In many countries, including the United States, it is a controlled substance. In others, it is legal to possess but not to sell or distribute.

See Also

• 25I-NBOMe
• 25C-NBOMe
• Psychedelic drug
• Hallucinogen
• Serotonin

‎